• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Imidazo[1,2-a]pyridin-2-ol (CAS No. 112566-20-8): A Versatile Heterocyclic Compound in Modern Pharmaceutical Research

The imidazo[1,2-a]pyridine scaffold, particularly its derivative imidazo[1,2-a]pyridin-2-ol (CAS 112566-20-8), has emerged as a pivotal structural motif in medicinal chemistry and drug discovery. This bicyclic heterocycle combines the pharmacophoric features of both imidazole and pyridine rings, endowing it with unique electronic properties and binding capabilities that are highly sought after in the design of bioactive molecules.

Recent advances in synthetic methodologies have enabled the efficient construction of imidazo[1,2-a]pyridine derivatives, with imidazo[1,2-a]pyridin-2-ol serving as a key intermediate for numerous therapeutic agents. The compound's hydrogen-bond donor/acceptor capacity at the 2-ol position makes it particularly valuable for targeting enzyme active sites and protein-protein interaction interfaces, addressing current challenges in precision medicine development.

In the context of trending pharmaceutical research, CAS 112566-20-8 has gained attention for its potential applications in kinase inhibitor design. With the growing market for targeted cancer therapies, researchers are exploring how modifications to the imidazo[1,2-a]pyridine core can enhance selectivity against specific oncogenic kinases while minimizing off-target effects - a frequent search topic among medicinal chemists in academic and industrial settings.

The compound's physicochemical properties have been extensively studied, revealing favorable drug-likeness parameters that comply with Lipinski's rule of five. This makes imidazo[1,2-a]pyridin-2-ol particularly attractive for lead optimization in drug discovery programs, especially for oral administration candidates. Recent publications highlight its improved metabolic stability compared to simpler heterocycles, addressing a common pain point in ADME optimization workflows.

Beyond oncology applications, CAS 112566-20-8 derivatives show promise in neurological disorders research, particularly as modulators of GABA receptors and ion channels. This aligns with current industry focus on CNS-penetrant molecules, as evidenced by increasing search volumes for "blood-brain barrier permeable compounds" in scientific databases. The scaffold's ability to adopt both planar and slightly puckered conformations contributes to its versatility in neuropharmacology applications.

From a synthetic chemistry perspective, imidazo[1,2-a]pyridin-2-ol offers multiple sites for structure-activity relationship (SAR) exploration. The 3-, 5-, and 8-positions can be selectively functionalized to tune electronic properties and steric bulk, while the 2-hydroxy group serves as an anchor point for prodrug strategies or additional pharmacophore attachment. These features have made it a frequent subject of combinatorial chemistry studies and high-throughput screening campaigns.

Environmental and green chemistry considerations have also influenced recent work with CAS 112566-20-8. Researchers are developing catalyst-free synthetic routes and microwave-assisted procedures to prepare this scaffold, responding to growing industry demand for sustainable synthetic methods. These advancements address frequently searched topics like "atom-economical heterocycle synthesis" in chemical literature databases.

The crystalline form of imidazo[1,2-a]pyridin-2-ol has been characterized by X-ray diffraction studies, revealing interesting supramolecular architectures through hydrogen bonding networks. This structural information is invaluable for cocrystal engineering approaches to improve solubility - a property frequently queried in pharmaceutical formulation searches. The compound's polymorphic behavior is currently under investigation to support quality by design (QbD) principles in drug development.

Analytical methods for CAS 112566-20-8 quantification have been refined using advanced techniques like UPLC-MS/MS, particularly important for metabolite identification studies. This responds to the increasing regulatory emphasis on impurity profiling throughout drug development, a hot topic in current pharmaceutical analysis discussions and frequent search term in quality control contexts.

In material science applications, the imidazo[1,2-a]pyridine core has shown potential in organic electronics due to its electron-transport properties. While imidazo[1,2-a]pyridin-2-ol itself is primarily used in life sciences, its derivatives are being explored for OLED materials and molecular sensors, connecting to trending searches about "heterocyclic semiconductors" and "bio-inspired materials."

The safety profile of imidazo[1,2-a]pyridin-2-ol has been documented in preliminary toxicological studies, showing favorable results for in vitro cytotoxicity screens. These findings support its continued investigation as a privileged scaffold in fragment-based drug design, particularly for targets requiring allosteric modulation - another area of growing interest in drug discovery circles.

As the pharmaceutical industry increasingly embraces AI-assisted molecular design, CAS 112566-20-8 has appeared in several cheminformatics studies as a reference compound for scaffold hopping algorithms. This application aligns with current searches for "machine learning in heterocyclic chemistry" and reflects the compound's relevance in modern computational drug discovery workflows.

Looking forward, imidazo[1,2-a]pyridin-2-ol derivatives are positioned to play significant roles in addressing drug resistance challenges through multi-targeting strategies. The scaffold's adaptability supports the design of hybrid molecules - a concept generating increasing search traffic as researchers seek solutions to complex disease mechanisms. With ongoing innovations in synthetic methodology and biological evaluation, CAS 112566-20-8 remains at the forefront of privileged structure research in medicinal chemistry.

• 274-76-0(Imidazo[1,2-a]pyridine)
• 69214-22-8(Imidazo[1,2-a]pyridin-8-ol)
• 79707-11-2(2-Methylimidazo[1,2-a]pyridin-8-ol)
• 874-39-5(7-Methylimidazo1,2-apyridine)
• 123444-29-1(Pyrido[1,2-a]benzimidazol-8-ol)
• 146469-95-6(3H-Purin-6-ol (9CI))
• 146469-94-5(7H-Purin-6-ol)
• 183208-36-8(5-methoxy-1H-pyrrolo[2,3-b]pyridine)
• 150359-30-1(Imidazo[1,2-a]pyrimidin-3-ol)
• 150359-29-8(imidazo1,2-apyridin-3-ol)